Compare · MRK vs ZTS
MRK vs ZTS
Side-by-side comparison of Merck & Company Inc. (MRK) and Zoetis Inc. (ZTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and ZTS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $323.72B, about 10.2x ZTS ($31.59B).
- Over the past year, MRK is up 55.8% and ZTS is down 50.0% - MRK leads by 105.8 points.
- ZTS has been more active in the news (14 items in the past 4 weeks vs 5 for MRK).
- MRK has more recent analyst coverage (25 ratings vs 24 for ZTS).
- Company
- Merck & Company Inc.
- Zoetis Inc.
- Price
- $131.06+0.43%
- $75.37+1.11%
- Market cap
- $323.72B
- $31.59B
- 1M return
- +8.66%
- -3.55%
- 1Y return
- +55.82%
- -50.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 5
- 14
- Recent ratings
- 25
- 24
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Latest MRK
- Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
- Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Latest ZTS
- Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
- Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
- SEC Form 4 filed by Executive Vice President Sarbaugh Keith
- SEC Form 4 filed by Chief Executive Officer Peck Kristin C
- SEC Form 4 filed by Executive Vice President Esch Kevin
- SEC Form 4 filed by Executive Vice President Nayak Abhay U
- SEC Form 4 filed by Executive Vice President Driscoll Rimma
- SEC Form 4 filed by Executive Vice President Fuller Julie
- SEC Form 4 filed by Executive Vice President Lagano Roxanne
- SEC Form 4 filed by Executive Vice President Ferran Astorga Jeannette